Catalytic asymmetric total synthesis of diazabicyclooctane beta-lactamase inhibitors avibactam and relebactam

Zhi Yang,Yu Chen,Linxi Wan,Xiangling Cen,Pei Tang,Fener Chen
DOI: https://doi.org/10.1039/d2cc04006a
IF: 4.9
2022-01-01
Chemical Communications
Abstract:A catalytic asymmetric total synthesis of avibactam and relebactam, two marketed diazabicyclooctane (DBO) beta-lactamase inhibitors (BLIs), has been accomplished. An important feature of this study is the creation of a stereogenic center by using Rh-catalysed asymmetric hydrogenation, affording the crucial alpha-amino acid ester derivative with high-level enantiocontrol (99% ee). Furthermore, the adoption of flow technologies for the assembly of a majority of intermediates significantly achieves a faster preparation and greater synthetic efficiency than corresponding batch procedures.
What problem does this paper attempt to address?